Stryker Co. (NYSE:SYK) Shares Acquired by Vise Technologies Inc.

Vise Technologies Inc. lifted its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 100.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,620 shares of the medical technology company's stock after buying an additional 1,812 shares during the period. Vise Technologies Inc.'s holdings in Stryker were worth $1,303,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. J. W. Coons Advisors LLC grew its holdings in Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after buying an additional 26 shares during the last quarter. Mascoma Wealth Management LLC grew its holdings in Stryker by 22.7% during the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after buying an additional 27 shares during the last quarter. Opal Wealth Advisors LLC grew its holdings in Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock valued at $654,000 after buying an additional 28 shares during the last quarter. Lindbrook Capital LLC grew its holdings in Stryker by 2.0% during the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after buying an additional 28 shares during the last quarter. Finally, Capital & Planning LLC grew its holdings in Stryker by 3.6% during the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock valued at $304,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Up 1.9%

NYSE:SYK traded up $7.04 during mid-day trading on Tuesday, hitting $383.66. The company had a trading volume of 1,099,109 shares, compared to its average volume of 1,347,413. The business has a fifty day simple moving average of $368.04 and a 200-day simple moving average of $376.15. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm has a market capitalization of $146.44 billion, a price-to-earnings ratio of 49.44, a PEG ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm's revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.50 EPS. Equities analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio (DPR) is 45.41%.

Wall Street Analyst Weigh In

SYK has been the topic of several analyst reports. Barclays raised their price objective on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Wall Street Zen cut Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. The Goldman Sachs Group set a $422.00 price objective on Stryker in a report on Tuesday, March 4th. BTIG Research set a $403.00 price objective on Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Finally, Argus set a $450.00 price objective on Stryker in a report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $427.30.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.90% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.